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Abstract
Background: Although tetrabenazine, a drug that depletes presynaptic dopamine by inhibiting vesicular monoamine transporter 2 (VMAT2), was approved by
the U.S. Food and Drug Administration in 2008 for the treatment of chorea associated with Huntington’s disease (HD), there is a paucity of data on its long-term
efficacy and safety.
Methods: Approximately 2,000 patients with a variety of hyperkinetic movement disorders had been treated with open-label tetrabenazine at the Movement
Disorders Clinic, Baylor College of Medicine, since 1979. Tetrabenazine was usually started at 12.5 mg/day, and the dosage was gradually increased (up to
300 mg/day). Responses were rated by the investigator 1–5, with 1 5 marked chorea reduction, excellent improvement in function; 2 5 moderate chorea
reduction, very good improvement in function; 35 fair chorea improvement, only mild improvement in function; 45 poor or no response for chorea and function;
and 5 5 worsening chorea, some functional deterioration. Efficacy and safety were analyzed retrospectively.
Results: By 2004, 98 HD chorea patients had received tetrabenazine for a mean of 3.1 years (range #1–11.4 years). Of those with valid ratings, 75% had either
marked or very good responses (rating 1 or 2) at their optimal dosages. The most common adverse events occurring in >5% of the patients were somnolence (39%),
insomnia (33%), depression (31%), accidental injury (26%), and dysphagia (19%). Efficacy and safety were comparable to results for non-HD chorea patients.
Discussion: Tetrabenazine treatment was associated with long-term improvement in chorea. Adverse event rates were comparable to those reported from
controlled trials.
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Introduction
Tetrabenazine is a potent, selective, reversible, and short-lasting
depletor of nerve terminal monoamines, especially dopamine.1,2 It
directly inhibits the presynaptic vesicular monoamine transporter 2
(VMAT2), which, in humans, is expressed almost exclusively in the
brain. Following oral administration, it is nearly completely absorbed
from the digestive tract and rapidly transformed through first-pass
metabolism in the liver by the enzyme carbonyl reductase into a pair of
stereoisomeric metabolites, a-dihydrotetrabenazine (a-HTBZ) and
b-HTBZ, which, in turn, are metabolized, again in the liver, primarily
by cytochrome P450 CYP2D6. Tetrabenazine and a-HTBZ (but not
b-HTBZ) are potent VMAT2 inhibitors. Circulating concentrations of
the two primary, first-pass metabolites vary markedly from patient to
patient, which may account for the substantial optimal dosing
variability observed between patients. The parent compound and its
two metabolites do not inhibit the major CYP450 isoforms, and,
therefore, concomitant administration of tetrabenazine with drugs that
are CYP450 substrates should not affect their metabolism. On the
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other hand, a-HTBZ and b-HTBZ are CYP2D6 substrates, and their
metabolism may be affected by CYP2D6 inhibitors.
Results from four controlled clinical trials,1,2,3–5 including the pivotal,
randomized controlled TetraHD study,3 supported the U.S. Food and
Drug Administration’s (FDA) approval of tetrabenazine for chorea
associated with Huntington’s disease (HD) in August 2008.1,2 Prior to
the FDA approval, U.S. patients were able to obtain the drug through
physician Investigational New Drug (IND) Applications. These IND
studies typically made tetrabenazine available as a ‘‘last resort’’ therapy,
when other medications had failed to provide satisfactory control.
Tetrabenazine was administered to selected patients with a wide range
of hyperkinetic disorders at the Parkinson’s Disease Center and
Movement Disorder Clinic (PDCMDC) at the Baylor College of
Medicine (BCM) under Dr. Jankovic’s IND study, beginning in 1979.6,7
This is the first full report of all patients with chorea that spans the
entire study period. Previous reports included those with other
hyperkinetic disorders and spanned only part of the full study
periods.6,7 Through this open-label, observational study of patients
treated between 1979 and 2004, we evaluated the long-term efficacy
and safety effects of tetrabenazine at optimal and other dosages, and
sought to determine whether efficacy and safety varied by subgroups of
patients based on the use of concomitant medications, particularly
antidepressants and neuroleptics, as well as chorea severity, all in a less
restrictive, real-world setting.
Methods
Patients were enrolled and treated at the PDCMDC under Protocol
H-721, ‘‘Compassionate Use of Tetrabenazine in the Treatment of
Hyperkinesias,’’ a single-center, open-label, individualized-dosage,
observational study.6,7 This study protocol was conducted in
accordance with FDA regulations for investigational new drugs
outlined in 21 Code of Fedeval Regulations (CFR), Sections 312, 50,
and 56, ‘‘Good Clinical Practice.’’ All patients signed an informed
consent approved by the BCM Institutional Review Board and were
videotaped before tetrabenazine therapy was begun.6,7
Patients
Patients with chorea were approached and offered the opportunity
to participate in the study if their chorea had been troublesome (i.e.,
chorea had to have interfered with activities of daily living,
occupational activities, and/or academic activities). Further, conven-
tionally available treatments for chorea had to have failed to provide
satisfactory symptomatic relief. Patients were excluded if they were
unwilling to comply with study requirements or were unable to provide
informed consent.
From 1980 to 1991, study patients were initially admitted to the
hospital for the start of tetrabenazine treatment and were monitored
for postural hypotension and other potential adverse effects. After
1991, because of the low incidence of adverse effects, all participants
began tetrabenazine therapy in the outpatient clinic.
At entry into the study, chorea severity generally ranged from
moderate to severe/disabling. We analyzed data from two subgroups
of HD patients to determine if there were differences in tetrabenazine
safety and efficacy for those with moderate chorea versus those with
severe/disabling chorea.
Dosing
Prior to 1991, tetrabenazine dosage was initiated at 25 mg/day, and
increased by 25 mg every several days until a total dosage of 150–
200 mg was achieved, or an adverse event occurred. The treatment
regimen was modified as the PDCMDC gained experience with
tetrabenazine. Beginning in 1991, tetrabenazine dosage was titrated
(by either 12.5- or 25-mg increments every 3–7 days) to achieve a
response without troublesome adverse events. If a troublesome adverse
event occurred, the dosage was down-titrated to the last greatest
tolerated dosage.
Outpatient visits were scheduled 6 weeks post treatment initiation
and every 3 months thereafter. Dosage, efficacy, and adverse events
were collected at each clinic visit and recorded on case report forms.
Disease severity and response ratings
Disease severity was determined by the investigator and rated on a
scale of 1–4: 1 5 mild, 2 5 moderate, 3 5 severe, and 4 5 disabling.
Efficacy responses to tetrabenazine were rated on a scale of 1–5: 15
marked chorea reduction, excellent improvement in function; 2 5
moderate chorea reduction, very good improvement in function; 3 5
fair chorea improvement, only mild improvement in function; 4 5
poor or no response for chorea and function; and 5 5 worsening
chorea, some functional deterioration.8 Functional improvement was
assessed by the ability to perform activities of daily living and was
based on information obtained from patients or their caretakers.8
A hierarchical algorithm was used to derive the ‘‘standard or best
dosage’’ a patient received. If the last dosage was received for at least
21 days, then this was considered the ‘‘standard or best dosage’’ for
that patient. If the last dosage was received for fewer than 21 days,
then the ‘‘standard or best dosage’’ was defined as the most recent
dosage received for at least 21 days. If neither of those criteria could be
met, then the ‘‘standard or best dosage’’ was that dosage received for
the greatest duration.
Concomitant medication use
Because patients with HD also exhibit neuropsychiatric symptoms,
they are often treated with antidepressants and neuroleptics. During the
study, participants were treated, when necessary, with other drugs
(including psychotropic drugs), as determined by the investigator.
Concomitant medications were recorded with start date (as month)
relative to the start of tetrabenazine. Length of time on the concomitant
medication was recorded in days. Analyses in relation to other
concomitant medications or adverse events were not conducted.
Safety evaluations
Safety and tolerability were evaluated primarily by documentation
of adverse events, which were elicited and recorded at each follow-up
visit. For each event, the investigator determined its relationship to
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tetrabenazine (probable, possible, unlikely, none), and categorized it as
‘‘severe’’ or ‘‘not severe.’’ The original terms used to identify adverse
events in the case report forms were translated into Coding Symbols
for a Thesaurus of Adverse Reaction Terms (COSTART)9 dictionary-
coded preferred terms at the time of the 2004 analysis. The number
and percentage of patients experiencing one or more adverse events
was tabulated by the onset date of the event (i.e., elapsed time since
start of treatment) and ‘‘standard or best dosage’’ of tetrabenazine.
Results
Patient disposition
From January 1979 through February 2004, 165 patients received
open-label tetrabenazine for the treatment of chorea. Complete
records were available for 145 patients. Of those, 98 had chorea
associated with HD. Analyses of these 145 patients were conducted to
assess long-term safety and efficacy of tetrabenazine for both HD and
non-HD chorea. In 2004, data were extracted from the BCM case
report forms into a database. The data transfer was audited, and the
data analyzed. Of the 165 patients listed in the PDCMDC clinic log as
having received tetrabenazine after being diagnosed with chorea, three
were subsequently found to have been misclassified. Full patient
disposition is provided in Figure 1.
Baseline demographics and clinical characteristics
Descriptive statistics were employed to summarize demographics,
dosing, and clinical variables for all 145 patients (Table 1) and patient
subsets (Table 2). Overall, patients with HD chorea and those with
non-HD chorea shared similar characteristics. The major difference
between the two groups was age. The HD chorea patients were, on
average, older (54.8 years, range 31–79 years) than the non-HD
chorea patients (mean age 44 years, range 3–80 years).
At study entry, of the entire group of 145 patients, chorea severity, as
determined by the investigator (J.J.), was rated as mild for one, moderate
for 69, severe for 59, and disabling for 16. Ninety-eight patients had
chorea associated with HD, and were categorized by either moderate
chorea (44) or severe/disabling chorea (54) at baseline. Overall, no
notable differences were observed between the two groups in sex, age,
time since symptom onset, length of study participation, and cumulative
tetrabenazine treatment. In addition, baseline demographics and
clinical characteristics, as well as time since first symptom onset, did
not appear to be different for patients who had received concomitant
antidepressants and neuroleptics compared with those who had not.
Etiologies of chorea for the non-HD chorea patients included
Sydenham’s chorea (7), tardive chorea (7), hemi-chorea (6), cerebro-
vascular chorea (4), congenital chorea (3), post-infection chorea (3),
Figure 1. Patient Disposition. 1At study cutoff on February 29, 2004, 118 of the 145 patients had withdrawn from treatment. Reasons for withdrawal included participation in
a double-blind clinical trial examining withdrawal from tetrabenazine (TBZ) (12%), adverse events (20%), insufficient efficacy (7%), disorder resolved (3%), death (10%), travel/
financial hardship (8%), and other (23%). Other reasons included the patient transferred care to another physician, the patient entered hospice or nursing home, inadequate follow-
up information, progression of Huntington’s Disease (HD), and surgical treatment of movement disorder. (2See Table 3.) TBE, tetrabenazine; HD, Huntington’s Disease.
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autoimmune chorea (2), static encephalopathy (2), unknown etiology
(3), and other (10).
Tetrabenazine dosage
Dosage was highly individualized and ranged from 12.5–300 mg/
day for HD chorea patients (Figure 2), which was similar for those with
non-HD chorea (12.5–150 mg/day). In addition, dosing was indepen-
dent of chorea severity. The average daily dosages for HD patients
with moderate chorea and severe/disabling chorea at baseline were
60.5 mg/day (range 16.9–138.1 mg/day) and 74.8 mg/day (range
21.4–225.5 mg/day), respectively.
Efficacy of tetrabenazine
Of the 145 total patients, 137 had valid response ratings. At any
time and dosage during the entire study, 59% were judged to have had
a marked response (efficacy rating 1), 49% had a very good response
(efficacy rating 2), 40% had a mild response (efficacy rating 3), 31%
had a poor response (efficacy rating 4), and 18% had worsened
(efficacy rating 5). (Some patients had different scores at different visits,
thus the total percentage exceeds 100%.) Responses for those with HD
chorea were 61% with marked, 53% with very good, 41% with mild,
and 33% with poor responses. In addition, 22% had worsened. Of
those with non-HD chorea, 56% had marked, 40% had very good,
38% had mild, and 27% had poor responses, while 11% had
worsened.
Optimal tetrabenazine dosage
At any time/dosage during the entire study, 83% of patients with
HD chorea had ‘‘marked or very good’’ improvement in chorea
symptoms and functioning (Figure 3A). At optimal dosage (dosage that
provided the greatest efficacy with tolerable adverse events), 75% of
patients had a ‘‘marked or very good’’ response to tetrabenazine
(efficacy ratings 1 and 2, respectively) (Fig. 3B).
Moderate versus severe/disabling HD chorea
Forty-two of 44 patients with moderate HD chorea and 50 of 54
with severe/disabling HD chorea had valid response ratings. At any
Table 1. Demographics and Patient Disposition
Demographic All Participants HD Chorea Non-HD Chorea
N5145 N598 N547
Sex, n (%)
Female 87 (60) 58 (59) 29 (62)
Age at study entry, mean (range), years 51.3 (3–80) 54.8 (31–79) 44 (3–80)
Ethnic origin, n (%)
African-American 10 (7) 7 (7) 3 (6)
Asian 3 (2) 1 (1) 2 (4)
Caucasian 112 (77) 78 (80) 34 (72)
Hispanic or Latino 12 (8) 6 (6) 6 (13)
Native Hawaiian or Pacific Islander 3 (2) 2 (2) 1 (2)
Other 4 (3) 3 (3) 1 (2)
Missing 1 (1) 1 (1)
Time since symptom onset, mean
(range), years
7.9 (0–55) 8.1 (0–35) 7.4 (0–55)
Length of study participation, mean
(range), years
2.6 (,1–13.1) 3.1 (,1–11.4) NA
Cumulative TBZ treatment duration
.2 years, n (%)
70 (48) 53 (54) NA
HD, Huntington’s Disease; NA, Not Available; TBZ, Tetrabenazine.
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dosage and time during the trial, of those with moderate chorea, 52%
were judged to have had a marked response to tetrabenazine, 52% had
a very good response, 45% had a mild response, 29% had a poor
response, and 17% had worsened. (Because of the length of the study
[25 years], some participants could have had more than one rating,
and, thus, one patient could be represented by multiple response
ratings. Hence, the total percentage exceeds 100%). Similarly, of those
with severe/disabling chorea, 68% were judged to have had a marked
response to tetrabenazine, 54% had a very good response, 38% had a
mild response, 36% had a poor response, and 26% had worsened.
(Some patients may have been counted more than once.) Overall, 79%
and 86% of those with moderate chorea and severe/disabling chorea,
respectively, had achieved a ‘‘marked or very good’’ response. At
‘‘standard or best dosage’’ at any time during the trial, 71% of patients
with moderate chorea had achieved a ‘‘marked or very good’’ response
compared with 78% for those with severe/disabling chorea.























Female 21 (48) 37 (69) 44 (62) 14 (52) 29 (55) 29 (64)
Age at study entry,
mean (range),
years









3.0 (,1–11) 3.2 (,1–9) 3.5 (,1–9) 2.1 (,1–11) 3.4 (,1–11) 2.7 (,1–8)
Cumulative TBZ
treatment duration
.2 years, n (%)
20 (45) 33 (61) 43 (61) 10 (37) 30 (57) 23 (51)
HD, Huntington’s Disease; TBZ, Tetrabenazine.
Figure 2. Distribution of Tetrabenazine Optimal Dosage. Data are missing for one patient. TBZ, Tetrabenazine.
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Concomitant medications
Other concomitant medications, including psychotropic medications,
were used when necessary during the study, as determined by the
investigator (Table 3). For most patients, concomitant treatment with an
antidepressant or a neuroleptic was not maintained for the entire length
of the study. Neither concomitant antidepressants nor neuroleptics
appear to have affected the duration of tetrabenazine treatment or
reasons for discontinuations (Table 4). A total of 34 patients received an
antidepressant and neuroleptic at some point during tetrabenazine
therapy. However, concomitant use of both types of medications did not
always overlap. Concomitant medication use in the HD chorea group at
baseline and during the study is detailed in Table 5.
Maximum anti-chorea responses to tetrabenazine were similar
across groups, whether or not HD chorea patients were receiving
concomitant antidepressants (Figure 4A) or neuroleptics (Fig. 4B) at
any time during the study.
Safety
Overall, 125 of the 145 (86%) patients in the safety analysis group
reported an adverse event, and most of these events were within the
nervous system (76%). A list of most common adverse events (>5%)
reported in the trial is provided in Table 6. Adverse events were
reported more frequently at tetrabenazine dosages greater than
optimal dosage than at optimal dosage (Table 7).
Fourteen patients died during the study period, and 11 of those had
a diagnosis of HD. Others included two patients with tardive chorea
and one with systemic lupus erythmatosis. Seven of the patients with
HD had end-stage HD/presumed end-stage HD listed as cause of
death. Other causes of death included gastrointestinal hemorrhage (1),
metastatic lung carcinoma (1), myocardial infarction (2), pneumonia
and respiratory failure, and unknown (2). Most deaths were thought
not to be a result of the study drug. For one patient, causes of death are
listed as end-stage HD and pneumonia (with preceding adverse event
Figure 3. Response to Tetrabenazine. (A) Response to tetrabenazine at any time with any dosage; (B) patients with ‘‘marked’’ and/or ‘‘moderate’’ response to
tetrabenazine with optimal dosage. For (A) and (B), patients could have been counted more than once, depending on response to treatment.
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of excessive salivation and pneumonia possibly related to tetrabena-
zine). There were no recorded deaths attributed to suicide.
A total of 40 of 145 (28%) patients reported depression during the
study period. Of these, 30 of 98 (31%) were patients with HD chorea
and 10 of 47 (21%) were patients with non-HD chorea. Depression
was judged to be related to tetrabenazine for 13 of 98 HD patients
(13%), and for 6 of 45 non-HD patients (13%). Three cases of suicidal
ideation were reported during the study period, two of which involved
patients with chorea associated with HD. Tetrabenazine was
discontinued for one of these three patients because of insufficient
efficacy. Tetrabenazine was continued uneventfully in the two
remaining patients (suicidal ideation eventually resolved in both).
The third patient was judged to have made a suicidal gesture. All three
patients were receiving concomitant antidepressants. In the case of the
suicidal gesture, the patient was hospitalized, antidepressants were
initiated, and tetrabenazine therapy was continued. The event
resolved, and the patient was eventually discharged from the hospital.
There were no completed suicides in this study.
Additional safety information is provided in Table 8.
Discussion
This observational, open-label study represents the largest and
longest running database of patients with HD and non-HD chorea
who received long-term tetrabenazine therapy. This study permits,
for the first time, indirect comparisons between the response to
tetrabenazine in patients with HD-associated chorea and the response
Table 3. Concomitant Medication Use During Study for All Patients and Subsets of Patients With and Without HD Chorea
All Participants HD Chorea Non-HD Chorea
N5145 N598 N547
Received >1 concomitant medication
during study, n (%)
141 (97) 95 (97) 46 (98)
Antidepressants 90 (62) 71 (72) 19 (40)
Benzodiazepines 67 (46) 45 (46) 22 (47)
Neuroleptics 68 (47) 53 (54) 15 (32)
HD, Huntington’s Disease.
Table 4. Treatment Status and Reasons for Tetrabenazine Discontinuation for Subsets of Patients with HD Chorea























Continuing treatment 9 (20) 10 (19) 14 (20) 5 (19) 10 (19) 9 (20)
Withdrawn from
treatment
35 (80) 44 (81) 57 (80) 22 (81) 43 (81) 36 (80)
Death 5 (11) 6 (11) 8 (11) 3 (11) 7 (13) 4 (9)
Adverse events 9 (20) 8 (15) 12 (17) 5 (19) 11 (22) 6 (13)
Lack of efficacy 1 (2) 3 (6) 3 (4) 1 (4) 4 (8) 0
Disorder resolved
spontaneously
0 1 (2) 0 1 (4) 0 1 (2)
Travel/financial
reasons
1 (2) 6 (11) 5 (7) 2 (7) 3 (6) 4 (9)
Other 25 (55) 20 (37) 31 (44) 13 (48) 19 (36) 25 (56)
HD, Huntington’s Disease.
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Table 5. Antidepressant and Neuroleptic Use by Patients with HD Chorea at Baseline and During Study
HD, N598 Antidepressants No
Antidepressants
Unknown Neuroleptics No Neuroleptics Unknown
Baseline, n (%) 32 (33) 52 (53) 14 (14) 12 (12) 73 (75) 13 (13)
During study, n (%) 71 (72)1 27 (98) 0 53 (54) 45 (46)2 0
HD, Huntington’s Disease.
1Some participants were receiving several antidepressants.
2Concomitant neuroleptic use ranged from an as-needed basis to concomitant use for 2,839 days for one patient.
Figure 4. Tetrabenazine Efficacy Ratings. (A) Tetrabenazine efficacy ratings for patients with or without antidepressant treatment. Patients either received an
antidepressant at any time during the study or never received an antidepressant during the study. (B) Tetrabenazine efficacy ratings for patients with or without
neuroleptic treatment. Patients either received a neuroleptic at any time during the study or never received a neuroleptic during the study. For (A) and (B), patients could
have been counted more than once. ATD, Antidepressant; NLP, Neuroleptic.
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in patients with other types of chorea with data from the full report of
all patients with chorea that spanned the entire study period (1979–
2004). Of the 145 patients included in the study, 98 had chorea
associated with HD, and 47 had chorea associated with other diseases.
The results suggest that tetrabenazine was comparably efficacious and
well-tolerated over the long run in the treatment of a variety of
choreas.
A total of 145 patients were followed during this open-label trial for
a period ranging from 1 to 11 years, much longer than other studies.
Further, 53 patients with HD were treated for more than 2 years, and
26 were treated for more than 4 years. By contrast, during TetraHD,
the pivotal double-blind, placebo-controlled study of tetrabenazine for
HD chorea,3 54 of the 84 patients received tetrabenazine for only 12
weeks. The long-term efficacy and safety data from this database
compares favorably with the short-term results from the TetraHD
study3 and provides evidence that tetrabenazine exerts long-term
benefits in patients with chorea. Of the 84 patients in TetraHD,3 75
(89%) continued into an open-label extension study for up to 80 weeks4
(approximately half the time of the BCM IND study). A more recent
open-label observational study, the Cooperative Huntington
Observational Research Trial (COHORT),10 included 149 partici-
pants receiving tetrabenazine at some time for the treatment of
HD chorea. Efficacy and tetrabenazine-related safety data from
COHORT have not yet been fully analyzed and published.
Of the 145 patients in this long-term observational study, 98 (67.5%)
had a diagnosis of HD. Limitations of this database include its open-
label design and retrospective analyses. In addition, although the
data were captured prospectively, the analyses were conducted
retrospectively, and baseline depression status and knowledge of
specific reasons for concomitant medication use were unknown,
especially for antidepressants and neuroleptics. Further, the patients
who respond to and tolerate the drug the best tend to remain in open-
label studies the longest. Finally, for some patients, the records did not
indicate precisely when they started receiving concomitant medica-
tions, when they stopped receiving them, and what adverse events
occurred during their concomitant medication periods.
Dosing was similar in all groups and, in keeping with previous
reports of tetrabenazine’s use, was highly individualized. It has been
hypothesized that, because of interindividual variations in carbonyl
reductase, tetrabenazine may be metabolized into varying ratios of the
alpha and beta metabolites. Currently, there have been no studies that
correlated the ‘‘optimal dosage’’ of tetrabenazine to circulating
metabolites. A recent retrospective study from BCM PDCMDC
sought to correlate the CYP2D6 genotype and the response to
tetrabenazine.11 The number of patients was too small to make any
correlations between CYP2D6 genotype and response, but the authors
concluded that knowledge of a patient’s CYP2D6 status (i.e., poor,
intermediate, extensive, or ultrarapid metabolizer) was not required to
manage that patient’s condition, as the dosage or titration adjustments
were individualized and made according to the observed response or
emergence of adverse events.11
Efficacy response rates did not differ between subgroups in this long-
term observational study, suggesting that response to tetrabenazine
does not seem to be affected by either severity of chorea, or use of
concomitant antidepressants or neuroleptics. While chorea was
measured differently, these data are consistent with what was observed







Somnolence 65 (45) 38 (39) 27 (57)
Insomnia 41 (28) 32 (33) 9 (19)
Depression 40 (27) 30 (31) 10 (21)
Accidental
injury
30 (21) 25 (26) 5 (11)
Dysphagia 22 (15) 19 (19) 3 (6)
Parkinsonism 20 (14) 11 (11) 9 (19)
Weight loss 21 (14) 17 (17) 4 (8)
Increased
salivation
19 (13) 12 (12) 7 (15)
Akathisia 17 (12) 12 (12) 5 (11)
Nervousness 16 (11) 11 (11) 5 (11)
Anxiety 15 (10) 11 (11) 4 (8)
Asthenia 15 (10) 10 (10) 5 (11)
Diarrhea 13 (9) 12 (12) 1 (2)
Nausea 13 (9) 10 (10) 3 (6)
Pain 12 (8) 5 (5) 7 (15)
Constipation 11 (8) 9 (9) 2 (4)
Dizziness 10 (7) 8 (8) 2 (4)
Urinary
incontinence
10 (7) 9 (9) 1 (2)
Agitation 9 (6) 8 (8) 1 (2)
Ataxia 9 (6) 7 (7) 2 (4)
Headache 9 (6) 4 (4) 5 (11)
Amnesia 8 (6) 5 (5) 3 (6)
Dysarthria 8 (6) 8 (8) 0
Speech
disorder
8 (6) 5 (5) 3 (6)
HD, Huntington’s Disease.
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in TetraHD,3 in which tetrabenazine-related decreases in chorea
scores were found to be not related to baseline chorea severity (as
measured by Clinical Global Impression of severity3), or chorea score
(as measured by the Unified Huntington’s Disease Rating Scale).
In all groups, there were slightly fewer patients reporting marked or
very good responses at their optimal dosages than when analyzed at
any dosage and time. This suggests that some individuals may have
had to decrease their dosages of tetrabenazine because of intolerable
adverse events, resulting in some loss of chorea control. Limitations in
assessing efficacy for those receiving or not receiving concomitant
medications stem from the inability to determine the concurrence of
the initiation, dosage change, and discontinuation of antidepressants or
neuroleptics with efficacy results. Of note, while concomitant
antidepressants were permitted during TetraHD,3 and could be
initiated during the trial, concomitant neuroleptics were not allowed at
any point during TetraHD,3 in contrast to this open-label observa-
tional study. Concomitant medications, including neuroleptics, were
added if the investigator felt they were required, reflecting a more real-
world clinical setting.
Overall, rates and types of adverse events were consistent with those
previously published in the placebo-controlled TetraHD trial.3
Adverse events occurred more frequently at greater than ‘‘optimal’’
dosages. Insomnia, depression, akathisia, nervousness, and parkinson-
ism appeared to have occurred more frequently in patients who had
received antidepressants during the study. Nervousness, asthenia, and
parkinsonism were more frequent in patients who had received a
neuroleptic. Interpretation of these results is complex, as adverse
events may not have occurred at the same time as when a concomitant
medication was received. For example, greater incidence of depression
in those who had received antidepressants may simply reflect the
reason why antidepressant treatment was initiated in these patients in
the first place. Indeed, antidepressants were often used effectively
to improve mood in patients with suspected tetrabenazine-induced
depression. Similarly, dopaminergic drugs were sometimes used to
treat tetrabenazine-induced parkinsonism. Furthermore, stimulants
(particularly modafinil and armodafinil) have been used to counteract
the sedative effects of tetrabenazine. Finally, anxiolytics and zolpidem
can be very useful in the treatment of tetrabenazine-induced
nervousness (anxiety) and akathisia.12
An ongoing concern with tetrabenazine, a monoamine depletor, has
been the potential for an increased risk of depression. The HD
population, as a whole, is at a greater risk of developing depression
than the general population, possibly as a result of underlying
depression, obsessive–compulsive behavior, and increased impulsiv-
ity.13 In TetraHD,3 there were eight adverse event reports of depressed
mood in those on the study drug, and no reports for those on the
placebo. Based on post-hoc analyses of TetraHD,3 the incidence of
depressed mood with tetrabenazine did not differ between those who
were receiving an antidepressant and those who were not.14 In this
open-label, observational chorea patient sample, there were 30 (31%)
reported adverse events of depression in the HD chorea group, while
10 (21%) of the non-HD chorea group reported depression. In
consideration of an adverse event of depression considered by the
investigator as being possibly or probably related to tetrabenazine, the
rate of depression was the same in both groups (13%). This suggests
that depression in some individuals with HD chorea receiving
tetrabenazine may be a result of underlying disease.
Another concern with the HD population is the risk of suicide. The
HD population, as a whole, is at a 10-times greater risk for suicide than
the general population.15 Moreover, it is the third most common cause
of death for patients with HD,16 and suicidal ideation has been
reported for 21.6% of those in Stage 2 HD.17 There was one suicide in
Table 7. Adverse Events at Best Dosage vs. Dosages Greater Than Best Dosage, All Possibly/Probably Related to Tetrabenazine
Adverse Event, n (%) At Best Tetrabenazine Dosage At Greater Than Best Tetrabenazine Dosage
All HD Non-HD All HD Non-HD
N5142 N596 N546 N565 N543 N522
Somnolence 20 (14%) 8 (8%) 12 (26%) 23 (35%) 16 (37%) 7 (32%)
Insomnia 9 (6%) 5 (5%) 4 (9%) 6 (9%) 5 (12%) 1 (5%)
Depression 7 (5%) 5 (5%) 2 (4%) 6 (9%) 4 (9%) 2 (9%)
Akathisia 4 (3%) 3 (3%) 1 (2%) 8 (12%) 6 (14%) 2 (9%)
Parkinsonism 6 (4%) 3 (3%) 3 (7%) 9 (14%) 4 (9%) 5 (23%)
Nervousness 7 (5%) 5 (5%) 2 (4%) 4 (6%) 3 (7%) 1 (5%)
Asthenia 1 (1%) 0 1 (2%) 5 (8%) 3 (7%) 2 (9%)
Nausea 4 (3%) 3 (3%) 1 (2%) 1 (2%) 1 (2%) 0
HD, Huntington’s Disease.
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Table 8. Adverse Events for Subsets of Patients With and Without HD Chorea, with Moderate vs. Severe/Disabling HD Chorea, and by Concomitant
Antidepressant or Neuroleptic Use for Those with HD Chorea.
HD Non-HD
N598 N547
Serious adverse event, n (%) 19 (19)1 5 (11)
Moderate HD chorea Severe/disabling HD chorea
Adverse event probably or possibly related
to TBZ, n (%)
n544 n554
Somnolence 19 (43) 12 (22)
Insomnia 7 (16) 8 (15)
Depression 10 (23) 6 (11)
Akathisia 3 (7) 8 (15)
Nervousness 3 (7) 7 (13)
HD HD
N598 N598
Received >1 concomitant antidepressant
during study
Yes No
n (%) 71 (72) 27 (28)
Adverse events probably or possibly related
to TBZ, n (%)
Somnolence 21 (30) 10 (37)
Insomnia 14 (20) 1 (4)
Depression 14 (20) 2 (7)
Akathisia 10 (14) 1 (4)
Nervousness 9 (13) 1 (4)
Parkinsonism 8 (11) 1 (4)
Nausea 5 (7) 2 (7)
Asthenia 6 (8) 0
Received >1 concomitant antidepressant
during study
Yes Yes
n (%) 71 (72) 71 (72)
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Received paroxetine or fluoxetine2 Yes No
n (%) 34 (48) 37 (52)
Adverse event (may or may not have been
related to TBZ
Somnolence 19 (56) 9 (24)
Depression 18 (53) 14 (38)
Insomnia 16 (47) 13 (35)
Accidental injury 11 (32) 11 (30)
Dysphagia 8 (24) 8 (22)
Weight loss 9 (26) 6 (16)
Akathisia 9 (26) 2 (5)
Increased salivation 6 (18) 3 (8)
Diarrhea 7 (21) 2 (5)
Anxiety 5 (15) 6 (16)
Parkinsonism 5 (15) 5 (14)
Nervousness 1 (3) 9 (24)
Urinary incontinence 7 (21) 2 (5)
HD HD
N598 N598
Received >1 concomitant neuroleptic
during study
Yes No
n (%) 53 (54) 45 (46)
Adverse events probably or possibly related
to TBZ, n (%)
Somnolence 19 (36) 12 (27)
Insomnia 8 (15) 7 (16)
Depression 9 (17) 7 (16)
Akathisia 4 (8) 7 (16)
Nervousness 8 (15) 2 (4)
Parkinsonism 6 (11) 3 (7)
Nausea 5 (9) 2 (4)
Asthenia 6 (11) 0
HD, Huntington’s Disease; TBZ, Tetrabenazine.
1Two patients had serious adverse events thought to be related to tetrabenazine: accidental injury (one patient); and psychosis, hallucinations, and insomnia (one
patient). Otherwise, serious adverse events were most commonly associated with the primary illness, such as HD, or a co-morbid medical condition such as lung
cancer, gastric ulcer, or accidental injury. Accidental injuries included falls, dislocated hip, lacerations, abrasions, and lip biting.
2Strong CYP2D6 inhibitors.
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TetraHD3 for a patient on the study drug. In this database, there was
one case of suicidal gesture in the HD chorea group (which resolved),
and there were three cases of suicidal ideation: two in the HD chorea
group and one in the non-HD chorea group. There were, however, no
suicides reported in our study of individuals treated with tetrabenazine
for chorea. A recent analysis of the COHORT database analyzed
1,413 individuals for more than 5 years.18 Of these, 149 individuals
were receiving tetrabenazine. For those exposed to tetrabenazine,
there were no suicide attempts or suicides completed.18 Of those 1,264
individuals not exposed to tetrabenazine, there were 17 suicide
attempts and four suicides, and suicidal ideation was either not
captured or not reported.18 Suicide and suicide attempts, while more
common for those with HD than for the general population, remain
rare events.
Although there were limitations in interpreting data from this
database, efficacy and rates of adverse events were consistent with those
observed in the double-blind, placebo-controlled study TetraHD.3
Efficacy and safety were comparable for HD and non-HD chorea; for
moderate and severe/disabling HD chorea; and for those receiving or
not receiving an antidepressant or a neurolpetic. We conclude that
tetrabenazine is efficacious and well-tolerated for the treatment of
chorea over both the short and the long terms.
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